ECSP066536A - Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma - Google Patents

Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma

Info

Publication number
ECSP066536A
ECSP066536A EC2006006536A ECSP066536A ECSP066536A EC SP066536 A ECSP066536 A EC SP066536A EC 2006006536 A EC2006006536 A EC 2006006536A EC SP066536 A ECSP066536 A EC SP066536A EC SP066536 A ECSP066536 A EC SP066536A
Authority
EC
Ecuador
Prior art keywords
proofisador
peroxisoma
dereceptor
derivatives
activated
Prior art date
Application number
EC2006006536A
Other languages
English (en)
Inventor
Gee-Hong Kuo
Aihua Wang
Lan Shen
Yan Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP066536A publication Critical patent/ECSP066536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a ácidos fenoxiacéticos y análogos de la fórmula (I), composiciones que los contienen, y métodos para usarlos como moduladores de PPAR para tratar o inhibir la progresión de, por ejemplo, dislipidemia.
EC2006006536A 2003-10-31 2006-04-28 Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma ECSP066536A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51656103P 2003-10-31 2003-10-31

Publications (1)

Publication Number Publication Date
ECSP066536A true ECSP066536A (es) 2006-12-20

Family

ID=34549548

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006536A ECSP066536A (es) 2003-10-31 2006-04-28 Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma

Country Status (21)

Country Link
US (3) US7015329B2 (es)
EP (1) EP1684752B1 (es)
JP (1) JP2007527416A (es)
KR (1) KR20060109925A (es)
CN (1) CN1897939A (es)
AR (1) AR046311A1 (es)
AT (1) ATE362367T1 (es)
AU (1) AU2004285530A1 (es)
BR (1) BRPI0416106A (es)
CA (1) CA2544317A1 (es)
CR (1) CR8377A (es)
DE (1) DE602004006529T2 (es)
EA (1) EA009804B1 (es)
EC (1) ECSP066536A (es)
ES (1) ES2287786T3 (es)
IL (1) IL175310A0 (es)
NO (1) NO20062511L (es)
TW (1) TW200528438A (es)
UA (1) UA84035C2 (es)
WO (1) WO2005041959A1 (es)
ZA (1) ZA200604420B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100877B1 (en) 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CN1897939A (zh) * 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
WO2006042245A1 (en) * 2004-10-11 2006-04-20 Dr. Reddy's Laboratories Ltd. Novel isoxazole compounds having ppar agonist activity
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
KR20090066289A (ko) 2006-09-08 2009-06-23 로드아일랜드하스피틀 알코올 유발성 뇌 질환의 치료, 예방 및 역행
CA2663115C (en) 2006-09-08 2015-04-28 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8426439B2 (en) 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
AU2011296737A1 (en) 2010-08-31 2013-04-11 Snu R&Db Foundation Use of the fetal reprogramming of a PPAR delta agonist
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
CA2871640A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Par4 agonist peptides
SMT201700457T1 (it) 2012-04-26 2017-11-15 Bristol Myers Squibb Co DERlVATI IMIDAZOTIADIAZOLICI E IMIDAZOPIRAZINICI COME INIBITORI DEL RECETTORE ATTIVATO DA PROTEASI 4 (PAR4) PER IL TRATTAMENTO DELL'AGGREGAZIONE PIASTRINICA
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN118359543A (zh) * 2023-01-18 2024-07-19 哈尔滨三联药业股份有限公司 五元杂环类化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4345230B2 (ja) * 1998-03-10 2009-10-14 小野薬品工業株式会社 カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
US6242493B1 (en) 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
PT1177176E (pt) 1999-04-28 2006-08-31 Aventis Pharma Gmbh Derivados de acidos triarilicos como ligandos de receptores ppar.
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
EP1310494B1 (en) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
AU2003299790A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
CN1897939A (zh) * 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物

Also Published As

Publication number Publication date
US20060074246A1 (en) 2006-04-06
US20090131489A1 (en) 2009-05-21
CR8377A (es) 2008-11-24
JP2007527416A (ja) 2007-09-27
TW200528438A (en) 2005-09-01
DE602004006529T2 (de) 2008-01-31
ATE362367T1 (de) 2007-06-15
EA009804B1 (ru) 2008-04-28
AU2004285530A1 (en) 2005-05-12
CA2544317A1 (en) 2005-05-12
EP1684752B1 (en) 2007-05-16
NO20062511L (no) 2006-07-27
IL175310A0 (en) 2006-09-05
US7015329B2 (en) 2006-03-21
KR20060109925A (ko) 2006-10-23
EP1684752A1 (en) 2006-08-02
AR046311A1 (es) 2005-11-30
EA200600878A1 (ru) 2006-10-27
DE602004006529D1 (de) 2007-06-28
CN1897939A (zh) 2007-01-17
UA84035C2 (ru) 2008-09-10
US7498351B2 (en) 2009-03-03
WO2005041959A1 (en) 2005-05-12
ES2287786T3 (es) 2007-12-16
BRPI0416106A (pt) 2007-01-02
US20050096362A1 (en) 2005-05-05
ZA200604420B (en) 2007-10-31

Similar Documents

Publication Publication Date Title
ECSP066434A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
CR8377A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles de receptor activado por proliferador de peroxisoma
NI200700075A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
UY28915A1 (es) Derivados de tetraazabenzo (e)azuleno y sus análogos
ECSP099327A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
UY28482A1 (es) Nuevos compuestos
ECSP088854A (es) Moduladores bencimidazolicos de vr1
AR053334A1 (es) Pirazolilcarboxanilidas
ECSP099071A (es) Agonistas de ep2
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY27853A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
NI200700074A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
MX339074B (es) Piperacinil y diacepanil benzamidas y benztioamidas.
ECSP11011346A (es) 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3
CR9391A (es) Derivados de indanil-piperazinas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP11011345A (es) 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
ECSP066435A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
UY29294A1 (es) Sulfonamido-macrocíclos y sus sales como inhibidoras de tie2, composición farmacéutica que comprende estos compuestos, método de prepararlos y su uso.
CR8334A (es) Isopentilcarboxanilidas para la lucha contra los microorganismos indeseables